Roche Holding AG - Company Snapshot & SWOT Analysis
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is one of the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.
Roche is also the in the forefront in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders.
Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,442 people worldwide.
Roche Holding AG reported revenue of CHF 59.497 billion for the FY 2018 which saw an increase of 6.73% compared to FY 2017. This revenue is expected to increase by 5% and reach CHF 62.472 billion by FY 2019. Roche Holding AG registered highest revenue from United States market at including royalties which accounted for 47.20% of its total sales in FY 2018.
In total three US national wholesale distributors represent approximately a third of the Roche’s revenues in FY 2018. The three US national wholesale distributors are McKesson Corp. with CHF 9 billion (2017: CHF 7 billion), AmerisourceBergen Corp. with CHF 7 billion (2017: CHF 6 billion) and Cardinal Health, Inc. with CHF 5 billion (2017: CHF 5 billion). Approximately 95% of these revenues were in the Pharmaceuticals operating segment, with the residual in the Diagnostics segment.
Spanning over 27 pages and 10 exhibits, “Roche Holding AG - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Roche Holding AG - Company Snapshot & SWOT Analysis Report
Roche is also the in the forefront in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders.
Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,442 people worldwide.
Roche Holding AG reported revenue of CHF 59.497 billion for the FY 2018 which saw an increase of 6.73% compared to FY 2017. This revenue is expected to increase by 5% and reach CHF 62.472 billion by FY 2019. Roche Holding AG registered highest revenue from United States market at including royalties which accounted for 47.20% of its total sales in FY 2018.
In total three US national wholesale distributors represent approximately a third of the Roche’s revenues in FY 2018. The three US national wholesale distributors are McKesson Corp. with CHF 9 billion (2017: CHF 7 billion), AmerisourceBergen Corp. with CHF 7 billion (2017: CHF 6 billion) and Cardinal Health, Inc. with CHF 5 billion (2017: CHF 5 billion). Approximately 95% of these revenues were in the Pharmaceuticals operating segment, with the residual in the Diagnostics segment.
Spanning over 27 pages and 10 exhibits, “Roche Holding AG - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Roche Holding AG - Company Snapshot & SWOT Analysis Report
- This report provides detailed information about Roche Holding AG including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for global pharmaceutical market.
- This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Roche Holding AG - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Roche Holding AG
3.3.1 Company Profile
3.1.2 Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
3.3.3 Roche Holding AG: Financial Performance
3.1.3.1 Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)
3.1.3.2 Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)
3.1.3.3 Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)
3.1.3.4 Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)
3.1.3.5 Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)
3.1.4 Roche Holding AG: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Roche Holding AG
Strengths
Weaknesses
Opportunities
Threats
3.1.6 Key Customers of Roche Holding AG
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Scope of the Roche Holding AG - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Roche Holding AG
3.3.1 Company Profile
3.1.2 Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
3.3.3 Roche Holding AG: Financial Performance
3.1.3.1 Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)
3.1.3.2 Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)
3.1.3.3 Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)
3.1.3.4 Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)
3.1.3.5 Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)
3.1.4 Roche Holding AG: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Roche Holding AG
Strengths
Weaknesses
Opportunities
Threats
3.1.6 Key Customers of Roche Holding AG
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Roche Holding AG
Exhibit 3.2 Contact Information of Roche Holding AG
Exhibit 3.3 Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain
Exhibit 3.4 Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)
Exhibit 3.5 Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 3.7 Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 3.8 Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 3.9 County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 3.10 Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 3.11 County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 3.12 Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 3.13 Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 3.14 SWOT Analysis of Roche Holding AG
Exhibit 3.15 Roche Holding AG Pharmaceuticals Product Pipeline
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Roche Holding AG
Exhibit 3.2 Contact Information of Roche Holding AG
Exhibit 3.3 Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain
Exhibit 3.4 Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)
Exhibit 3.5 Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 3.7 Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 3.8 Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 3.9 County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 3.10 Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 3.11 County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 3.12 Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 3.13 Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 3.14 SWOT Analysis of Roche Holding AG
Exhibit 3.15 Roche Holding AG Pharmaceuticals Product Pipeline
